课题基金 / 基金详情

AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS

AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS
AVONEX (IFN B1A) 用于多发性硬化症高风险受试者
批准号：
6309272
负责人：
STALEY armstrong BROD
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2001-02-28
来源：
https://reporter.nih.gov/project-details/6309272
关键词：
clinical research disease /disorder prevention /control drug administration routes human subject human therapy evaluation immunopathology chemotherapy immunotherapy interferon beta longitudinal human study multiple sclerosis nervous system disorder chemotherapy placebos

项目摘要

项目成果

STALEY armstrong BROD的其他基金

相关文献

中文摘要
翻译
Avonex是一种重组人β干扰素产品，是成纤维细胞经病毒感染诱导后产生的一种抗病毒蛋白。这项随机、双盲、安慰剂对照研究将确定，在经历过首次和最近发生脱髓鞘事件的受试者以及多发性硬化症的高风险受试者中，Avonex是否有助于延缓临床明确的多发性硬化症的发病。总共有380名受试者将在长达三年的时间里每周接受一次Avonex或安慰剂的IM注射。
英文摘要
AVONEX, a recombinant human interferon-beta product, is an antiviral protein produced by fibroblasts after induction by viral infection. This randomized, double-blinded, placebo-controlled study will determine if AVONEX is beneficial in delaying the onset of clinically definite multiple sclerosis in subjects who have experienced a first and recent onset of a demyelinating event, and who are at high risk for multiple sclerosis. A total of 380 subjects will be treated with IM injections of AVONEX or placebo weekly for up to three years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IFNA: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES MELLITUS
PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE VIA INGESTED IFN-ALPHA
PROTEIN BIOMARKERS OF IFN-ALPHA IN MS
INGESTED IFN-A: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES